hepurposeofthisreportwastoupdatethe2006InternationalLeagueAgainstEpilepsy(ILAE)reportandidentifythelevelofevidenceforlong-termefficacyoreffectivenessforantiepilepticdrugs(AEDs)asinitialmonotherapyforpatientswithnewlydiagnosedoruntreatedepilepsy.AllapplicablearticlesfromJuly2005untilMarch2012wereidentified,evaluated,andcombinedwiththepreviousysis(Glauseretal.,2006)toprovideacomprehensiveupdate.
Thepriorysismethodologywasutilizedwiththreemodifications:(1)thedetectablenoninferiorityboundaryapproachwasdroppedandbothfailedsuperioritystudiesandprespecifiednoninferioritystudieswereyzedusinganoninferiorityapproach,(2)thedefinitionofanadequatecomparatorwasclarifiedandnowincludesanabsoluteminimumpointestimateforefficacy/effectiveness,and(3)therelationshiptablebetweenclinicaltrialratings,levelofevidence,andconclusionsnolongerincludesarecommendationcolumntoreinforcethatthisreviewofefficacy/evidenceforspecificseizuretypesdoesnotimplytreatmentrecommendations.
Thisevidencereviewcontainsoneclarification:ThecommissionhasdeterminedthatclassIsuperioritystudiescanbedesignedtodetectuptoa20?solute(ratherthanrelative)differenceinthepointestimateofefficacy/effectivenessbetweenstudytreatmentandcomparatorusinganintent-to-treatysis.SinceJuly,2005,threeclassIrandomizedcontrolledtrials(RCT)and11classIIIRCTshebeenpublished.Thecombinedysis(1940-2012)nowincludesatotalof64RCTs(7withclassIevidence,2withclassIIevidence)and11meta-yses.
Newefficacy/effectivenessfindingsincludethefollowing:levetiracetamandzonisamidehelevelAevidenceinswithpartialonsetseizuresandbothethosuximideandvalproicacidhelevelAevidenceinchildrenwithchildhoodabsenceepilepsy.
Therearenomajorchangesinthelevelofevidenceforanyothersubgroup.LevetiracetamandzonisamidejoincarbamazepineandphenytoinwithlevelAefficacy/effectivenessevidenceasinitialmonotherapyforswithpartialonsetseizures.AlthoughethosuximideandvalproicacidnowhelevelAefficacy/effectivenessevidenceasinitialmonotherapyforchildrenwithabsenceseizures,therecontinuestobeanalarminglackofwelldesigned,properlyconductedepilepsyRCTsforpatientswithgeneralizedseizures/epilepsiesandinchildreningeneral.
Thesefindingsreinforcetheneedformulticenter,multinationaleffortstodesign,conduct,andyzefutureclinicallyrelevantadequatelydesignedRCTs.Whenselectingapatient'sAED,allrelevantvariablesandnotjustefficacyandeffectivenessshouldbeconsidered.
查看信源地址
编辑:jiang- 2022-04-25隐源性哮喘死亡率翻倍
- 2022-04-132016AAN:神经专家发表了有前途的专业见解
- 2022-04-12北京癫痫手术费用
- 2022-04-11特发性癫痫大发作药物治疗的首选
- 2022-04-07【用药问答】癫痫发作和局限性发作的首选治疗是什么?
- 2022-04-06心理百科:春节期间小心疾病
- 北京癫痫手术费用
- 特发性癫痫大发作药物治疗的首选
- FDA批准Aptiom用于治疗患者癫痫发作
- 【用药问答】癫痫发作和局限性发作的首选治疗是什么?
- 心理百科:春节期间小心疾病
- 2015 神经系统疾病诊疗进展
- 综述:癫痫持续状态诊治最新进展
- 癫痫治疗障碍仍难以克服
- 治疗脑炎后遗症的方法有哪些?
- 2015第31届国际癫痫大会(IEC)
- 手术学习:颅内脊索瘤内镜下三脑室入路治疗
- 脑梗死的症状是什么有这些前兆要谨慎
- 癫痫猝死:凶手是谁?
- 预测癫痫患者再入院风险
- FDA批准开浦兰治疗1个月至4岁癫痫儿童
- 癫痫患者如何克服忘记吃药的问题?
- 癫痫治愈费用
- 早期癫痫的症状是什么?
- UCB的Vimpat癫痫新适应症在美国获批
- 英国竞争监管机构指控辉瑞癫痫药品价格过高
- 肺源性心脏病可能并发左心功能不全吗?如何制定治疗方案?
- 癫痫发作对中风患者静脉溶栓的长期转移有效
- 第四届全国临床脑电图实践基础理论与实践操作培训班
- Circ Ep:左室肥厚高血压患者新发房颤增加SCD风险
- 癫痫患者手术评估新型工具
- 抗癫痫药物预防新发癫痫:任重而道远
- 2013国际抗癫痫联合会抗癫痫药用指南
- 临床试验方案修订版对临床试验结果和费用的影响
- 戴只手表就能测癫痫发作?智能穿戴电子元件太牛了
- 引发癫痫病复发原因
- 癫痫的妇科治疗有几种,你知道吗?
- 成员国扩展批准优时比抗癫痫药物 Vimpat 用于儿童患者
- 父母怎样分辨孩子是不是癫痫?出现这些症状,家长不可这段话!
- 羊角风得病可以生孩子吗
- 新版医保药品远超2800种 “逢进必谈”的药都有哪些?一起来看!
- 上海率先探索异地就医门诊费用直接股票交易
- 延迟型癫痫发作病征卒中预后更差
- 用药癫痫病最佳
- 56个药同桌,涉一批药企:恒瑞、石药、扬子江…
- 癫痫病需要怎样来透过诊断